Checkpoint Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights
August 14, 2023 16:15 ET
|
Checkpoint Therapeutics, Inc
Biologics License Application for cosibelimab under review by U.S. FDA; Successful mid-cycle meeting with U.S. FDA completed; PDUFA goal date of January 3, 2024 Longer-term cosibelimab results...
GLOBALLY RECOGNIZED ROSEN LAW FIRM Encourages ImmunityBio, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – IBRX
July 27, 2023 11:33 ET
|
The Rosen Law Firm PA
NEW YORK, July 27, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ImmunityBio, Inc. (NASDAQ: IBRX) between May 23, 2022 and...
GLOBALLY RECOGNIZED ROSEN LAW FIRM Encourages ImmunityBio, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – IBRX
July 21, 2023 22:25 ET
|
The Rosen Law Firm PA
NEW YORK, July 21, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ImmunityBio, Inc. (NASDAQ: IBRX) between May 23, 2022 and May...
Aridis Pharmaceuticals' AR-301 Eligible for Consideration under FDA’s Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD)
June 20, 2023 08:00 ET
|
Aridis Pharmaceuticals, Inc.
LPAD may provide alternative pathways for streamlined product approval LOS GATOS, Calif., June 20, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical...
Checkpoint Therapeutics Reports First Quarter 2023 Financial Results and Recent Corporate Highlights
May 15, 2023 16:15 ET
|
Checkpoint Therapeutics, Inc
WALTHAM, Mass., May 15, 2023 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial...
ImmunityBio Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm
May 11, 2023 10:04 ET
|
Block & Leviton LLP
BOSTON, May 11, 2023 (GLOBE NEWSWIRE) -- Block & Leviton is investigating ImmunityBio, Inc. (NASDAQ: IBRX) for potential securities law violations. Investors who have lost money in their...
Alvotech Investigated For Potential Securities Law Violations by Block & Leviton LLP; Investors Who Have Lost Money Are Encouraged to Contact the Firm
April 14, 2023 11:22 ET
|
Block & Leviton LLP
BOSTON, April 14, 2023 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Alvotech (NASDAQ: ALVO) for potential securities law violations. Investors who have lost money in their Alvotech...
MacroGenics Earns $15 Million Milestone Following U.S. FDA Approval of ZYNYZ™ (retifanlimab-dlwr)
March 22, 2023 13:22 ET
|
MacroGenics, Inc.
ROCKVILLE, MD, March 22, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for...
Checkpoint Therapeutics Announces FDA Filing Acceptance of Biologics License Application for Cosibelimab in Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma
March 02, 2023 07:00 ET
|
Checkpoint Therapeutics, Inc
Prescription Drug User Fee Act (“PDUFA”) goal date of January 3, 2024 FDA indicates that it does not currently plan to hold an advisory committee meeting WALTHAM, Mass., March 02, 2023 (GLOBE...
Checkpoint Therapeutics Submits Biologics License Application to FDA for Cosibelimab as a Treatment for Patients with Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma
January 04, 2023 08:00 ET
|
Checkpoint Therapeutics, Inc
WALTHAM, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced the...